SKYEEarnings•globenewswire•
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Sentiment:Negative (10)
Summary
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the second quarter ended June 30, 2025, along with key accomplishments and upcoming milestones.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire